Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Sarcoma, Ewing 1Prostatic Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Colorectal Neoplasms 1Advanced Non-Hematologic Malignancies 1Advanced Cancer 1

Interventions

Cyclophosphamide 9Topotecan 5Temozolomide 5Melphalan 5Irinotecan 5Busulfan 5fludarabine 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4liposomal doxorubicin 3fludarabine phosphate 3cabozantinib 3Vincristine 3regorafenib 2pegfilgrastim 2Sirolimus 2Doxorubicin 2Bone Marrow Transplantation 2trioctyl phosphine oxide 1trifluridine tipiracil drug combination 1thymoglobulin 1talazoparib 1selinexor 1seclidemstat 1racotumomab 1poly ICLC 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1olaparib 1niraparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Sarcoma, Ewing × figitumumab × Clear all
NCT00474760 2013-12-17

Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

Pfizer

Phase 1 Completed
65 enrolled 35 charts
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡